Entrada Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Standard Sarbanes-Oxley certifications signed by Dipal Doshi (CEO) and Kory Wentworth (CFO) on August 5, 2026 for the quarter ended June 30, 2026. Both officers certify the 10-Q contains no untrue material statements, fairly presents financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No changes to internal controls are disclosed.
Why this rating
Routine SOX compliance certificate; no substantive business event, transaction, or financial change disclosed.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.